Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial

• Published in: JNCI : Journal of the National Cancer Institute 2021-09, Vol.113 (9), p.1228-1237
• Main Authors: Patil, Vijay Maruti, Singhai, Pankaj, Noronha, Vanita, Bhattacharjee, Atanu, Deodhar, Jayita, Salins, Naveen, Joshi, Amit, Menon, Nandini Sharrel, Abhyankar, Anuja, Khake, Ashwini, Dhumal, Sachin Babanrao, Tambe, Rupali, Muckaden, Mary Ann, Prabhash, Kumar
• Format: Article
• Language: English
• Subjects: Carcinoma, Squamous Cell - therapy; Head and Neck Neoplasms - therapy; Humans; Palliative Care - methods; Quality of Life
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/djab020

Early palliative care (EPC) is an important aspect of cancer management but, to our knowledge, has never been evaluated in patients with head and neck cancer. Hence, we performed this study to determine whether the addition of EPC to standard therapy leads to an improvement in the quality of life (QOL), decrease in symptom burden, and improvement in overall survival. Adult patients with squamous cell carcinoma of the head and neck region planned for palliative systemic therapy were allocated 1:1 to either standard systemic therapy without or with comprehensive EPC service referral. Patients were administered the revised Edmonton Symptom Assessment Scale and the Functional Assessment of Cancer Therapy for head and neck cancer (FACT-H&N) questionnaire at baseline and every 1 month thereafter for 3 months. The primary endpoint was a change in the QOL measured at 3 months after random assignment. All statistical tests were 2-sided. Ninety patients were randomly assigned to each arm. There was no statistical difference in the change in the FACT-H&N total score (P = .94), FACT-H&N Trial Outcome Index (P = .95), FACT-general total (P = .84), and Edmonton Symptom Assessment Scale scores at 3 months between the 2 arms. The median overall survival was similar between the 2 arms (hazard ratio for death = 1.01, 95% confidence interval = 0.74 to 1.35). There were 5 in-hospital deaths in both arms (5.6% for both, P = .99). In this phase III study, the integration of EPC in head and neck cancer patients did not lead to an improvement in the QOL or survival.